Saturday 17 October 2026 Export CORT’s income statement to Excel — free account

Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024. In the quarter to June 2026, revenue grew 31.7%, EPS grew 21.2% and free cash flow fell 29.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.

110.16 3.21 −2.83%

Follow CORT

Alert me

Market cap: $12.3B
P/E: 212×
Fwd P/E: 139×
Dividend yield: —
F-score: 4/9
Altman Z: 14.11
Beneish M: −2.76
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 3.31

Total sells 100.03

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	—	—	—	—	—	—	—
Sell	5	4	1	1	3	1	4	7	5	11	5	3

Insider Ownership 9.12%

Capital & Financial Ratios $m

Market Cap 12,260.00

Revenue 830.81

Net Income 55.18

Free Cash Flow 106.92

Net Debt (308.20)

Current Ratio 2.86

Debt/Equity 0.00

P/E ratio 211.85

Fwd P/E 139.00

P/S ratio 13.97

P/B ratio 16.45

Past 5Y EPS Growth (0.72%)

This Y EPS Growth 148.24%

Next Y EPS Growth 110.83%

Next Y revenue growth 50.51%

Next 5Y EPS Growth 104.08%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 94.90%

10-year low 10-year high

P/S against its own 10 years 92.26%

10-year low 10-year high

P/B against its own 10 years 79.47%

10-year low 10-year high

EV/Sales against its own 10 years 92.37%

10-year low 10-year high

EV/FCF against its own 10 years 95.83%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	368	383	372	308
Receivables	41	54	60	77
Inventory	8	12	13	13
Other	14	—	—	—
	459	472	485	440

	2023	2024	2025	Q'26
Payables	17	15	40	15
ST’ Debt	—	—	—	—
Other	14	—	—	—
	105	141	166	154

Compound Annual Growth %

	10y	5y	3y
Sales	31.23%	16.56%	23.74%
Cash Flow	46.44%	(1.35%)	5.68%
Earnings	0.00%	(1.52%)	(1.04%)
Book Value	42.70%	4.36%	8.88%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	165	256	—	—	—
’25	157	194	208	202	761
’24	147	164	183	182	675
’23	106	118	124	135	482
’22	94	103	102	103	402
’21	79	92	96	99	366
’20	93	89	86	86	354

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(17)	34	—	—	—
’25	5	44	54	38	142
’24	24	41	73	60	198
’23	26	42	53	6	127
’22	35	18	34	33	120
’21	25	44	49	49	168
’20	33	53	30	35	152

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(17)	31	—	—	—
’25	5	44	54	38	142
’24	24	41	72	60	196
’23	26	42	53	6	127
’22	35	18	33	33	120
’21	25	44	49	49	167
’20	33	53	30	35	151

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.30)	0.36	—	—	—
’25	0.17	0.29	0.16	0.20	0.82
’24	0.25	0.32	0.41	0.26	1.23
’23	0.14	0.25	0.28	0.28	0.94
’22	0.20	0.24	0.30	0.14	0.87
’21	0.18	0.21	0.24	0.17	0.89
’20	0.25	0.23	0.17	0.20	0.85

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3.22	6.70	11.21	9.14	9.70	15.83	16.47	17.86	20.84	32.99	Analyst estimates 2026–2028 Powerpack
	High	10.00	20.77	25.96	17.48	27.78	31.18	30.14	34.28	62.22	117.33
People
People	Employees	103	136	166	206	236	238	299	352	500	730
	Revenue/emp, $m	0.79	1.17	1.51	1.49	1.50	1.54	1.34	1.37	1.35	1.04
Income, $m
Income, $m	Revenue	81	159	251	306	354	366	402	482	675	761
	Gross margin, %	97.47	97.77	97.92	98.20	98.42	98.56	98.66	98.66	98.39	98.30
	EBT	8	53	92	117	132	125	116	125	161	66
	EBT margin, %	10.01	33.17	36.68	38.07	37.19	34.16	28.91	25.82	23.92	8.73
	Net income	8	129	75	94	106	113	101	106	141	100
	Depreciation	0	0	(1)	2	2	9	5	(7)	(10)	(3)
Per share, $
Per share, $	Revenue	0.74	1.40	2.18	2.68	3.07	3.16	3.76	4.66	6.54	7.33
	Earnings	0.07	1.14	0.65	0.82	0.92	0.97	0.95	1.02	1.35	0.95
	Cash flow	0.17	0.54	1.00	1.19	1.32	1.45	1.13	1.22	1.92	1.37
	Capex	0.00	0.00	0.00	(0.01)	(0.01)	0.00	0.00	0.00	(0.02)	0.00
	Free cash flow	0.16	0.53	1.00	1.18	1.31	1.45	1.12	1.22	1.90	1.37
	Book value	0.37	1.68	2.39	3.25	4.53	3.25	4.70	4.89	6.58	6.24
	Shares, m	111	114	115	114	115	116	107	104	103	104
Valuation, ×
Valuation, ×	P/E	105.44	16.05	20.55	14.58	28.43	22.76	21.23	23.46	37.33	37.02
	P/S	10.01	12.94	6.13	4.51	8.53	6.26	5.36	5.19	7.71	4.75
	P/B	19.67	10.78	5.59	3.73	5.77	6.09	4.29	4.94	7.65	5.58
	EV/Sales	9.60	12.47	5.37	3.65	7.32	5.68	4.31	4.45	7.16	4.28
	EV/FCF	42.90	32.79	11.69	8.29	17.18	12.41	14.45	16.95	24.65	22.97
Cash, $m
Cash, $m	Operating cash flow	18	61	116	136	152	168	120	127	198	142
	Capex	0	0	0	(1)	(1)	0	0	0	(2)	0
	Free cash flow	18	61	115	135	151	167	120	127	196	142
Balance, $m
Balance, $m	Working capital	38	95	201	269	431	219	427	354	331	319
	Total debt	15	—	—	2	1	1	1	—	6	5
	Net debt	(37)	(89)	(207)	(274)	(440)	(224)	(432)	(368)	(377)	(367)
	Shareholders’ equity	41	191	276	371	523	376	502	507	680	648
Returns, %
Returns, %	ROA	13.49	89.27	28.34	26.02	21.55	22.60	20.11	17.51	19.11	11.71
	ROIC	141.16	32.32	80.92	71.82	96.37	51.09	100.32	48.42	28.31	9.98
	ROE	27.19	111.15	32.31	29.11	23.70	25.03	23.08	20.92	23.56	14.79

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
JAZZ Jazz Pharmaceuticals PLC	$13.9B	13.8×	17.3×	+15.55% (above 0%: growing)	n/m	+140.99% (above 0%: growing)	90.37%	20.54%	Compare
HALO Halozyme Therapeutics, Inc.	$13.8B	34.6×	10.6×	+47.67% (above 0%: growing)	+44.12% (above 0%: growing)	+141.18% (above 0%: growing)	83.54%	59.80%	Compare
BBIO BridgeBio Pharma, Inc.	$13.1B	— (loss-making)	— (loss-making)	+120.39% (above 0%: growing)	n/m	+16.59% (above 0%: growing)	93.83%	(43.94%)	Compare
CORT Corcept Therapeutics Incorporated	$12.3B	212×	139×	+31.74% (above 0%: growing)	+21.21% (above 0%: growing)	−29.89% (below 0%: shrinking)	98.41%	16.12%
SMMT Summit Therapeutics PLC	$12.3B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−112.80% (below 0%: shrinking)	0.00%	0.00%	Compare
TECH Bio-Techne Corp	$11.4B	62.0×	37.6×	+1.33% (above 0%: growing)	n/m	−6.83% (below 0%: shrinking)	65.82%	23.13%	Compare
BMRN BioMarin Pharmaceutical Inc.	$10.9B	144×	16.1×	+19.91% (above 0%: growing)	−81.60% (below 0%: shrinking)	−20.28% (below 0%: shrinking)	79.51%	11.21%	Compare
MDGL Madrigal Pharmaceuticals, Inc.	$10.6B	— (loss-making)	— (loss-making)	+71.17% (above 0%: growing)	n/m	+140.54% (above 0%: growing)	89.02%	(15.46%)	Compare
IBRX ImmunityBio, Inc.	$10.6B	— (loss-making)	— (loss-making)	+93.91% (above 0%: growing)	n/m	+13.38% (above 0%: growing)	99.42%	(120.41%)	Compare
Median of peers	$11.8B	48.3×	16.7×	+33.79%	—	+14.98%	86.28%	5.61%

All 614 Biotechnology stocks →

Corcept Therapeutics Incorporated (CORT) key facts

Strength: Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.
Corcept Therapeutics Incorporated (CORT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CORT traded at $110.16, a market capitalization of $12.3 billion.
Return on equity was 14.8% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 14.11 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.